Misplaced Pages

Rifasutenizol

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (November 2024)

Pharmaceutical compound
Rifasutenizol
Identifiers
IUPAC name
  • -6,23-dioxospirotritriaconta-1(31),2,4,9,19,21,25(32),26,29-nonaene-28,4'-piperidine]-13-yl] acetate
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC48H61N7O13
Molar mass944.052 g·mol
3D model (JSmol)
SMILES
  • C1/C=C/C=C(\C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)O(C4=O)(O/C=C/((((((1O)C)O)C)OC(=O)C)C)OC)C)C5=NC6(CCN(CC6)CCN7C(=NC=C7(=O))C)N=C25)O)/C
InChI
  • InChI=InChI=1S/C48H61N7O13/c1-23-12-11-13-24(2)46(62)50-38-37-36(51-48(52-37)15-17-53(18-16-48)19-20-54-29(7)49-22-32(54)55(63)64)33-34(42(38)60)41(59)28(6)44-35(33)45(61)47(9,68-44)66-21-14-31(65-10)25(3)43(67-30(8)56)27(5)40(58)26(4)39(23)57/h11-14,21-23,25-27,31,39-40,43,57-60H,15-20H2,1-10H3,(H,50,62)/b12-11+,21-14+,24-13-/t23-,25+,26+,27+,31-,39-,40+,43+,47-/m0/s1
  • Key:OZUTUJQHZGJOKZ-AIGATTFSSA-N

Rifasutenizol is an investigational new drug developed by TenNor Therapeutics, primarily aimed at treating Helicobacter pylori infections. It is a novel multi-targeting small molecule that functions as a bacterial DNA-directed RNA polymerase inhibitor. This drug has been granted Qualified Infectious Disease Product and Fast Track designations by the U.S. FDA.

References

  1. "Rifasutenizol - TenNor Therapeutics". AdisInsight. Springer Nature Switzerland AG.
  2. Li X, Liu Y, Wang M, Gao L, Liu J, Zhang H, et al. (June 2024). "Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trials". The Lancet. Infectious Diseases. 24 (6): 650–664. doi:10.1016/S1473-3099(24)00003-3. PMID 38359854.
  3. "TenNor Announces Positive Topline Results from Rifasutenizol Phase III Trial for H. pylori Infection". 18 November 2024. Retrieved 24 November 2024.
  4. "Efficacy and Safety of Rifasutenizol (TNP 2198) in Participants With H. pylori Infection". Retrieved 24 November 2024.
  5. "Rifasutenizol - Drug Targets, Indications, Patents - Patsnap Synapse". Retrieved 24 November 2024.


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: